• About Adcendo
    • The Story
    • Leadership team
    • Board of Directors
    • Senior Scientific Founders
    • Clinical and Scientific Advisory Board
  • Our science
    • What are ADCs
    • The uPARAP receptor
    • Key publications
  • Investors
    • Corporate presentation
    • Press releases
    • Our investors
  • Careers
    • Open Positions
    • Company values
  • Contact

Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180 (2016)

Apr 26, 2016

Recent Posts

  • Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
  • GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate
  • Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
  • Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting
  • Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Recent Comments

No comments to show.

Adcendo ApS

For all inquiries, please contact adcendo via the e-mail address info@adcendo.com



Privacy Policy
© Adcendo ApS, All rights reserved 2022